The effects of angiotensin receptor blockers as prophylactic migraine treatment: A systematic review and meta-analysis
Abstract
BackgroundThe role of angiotensin II receptor blockers (ARBs) in migraine prophylaxis varies globally, partly due to insufficient evidence from randomized controlled trials (RCTs) supporting their efficacy. We aimed to conduct a systematic review and meta-analysis of ARBs in migraine prophylaxis.MethodsWe searched PubMed/MEDLINE, Embase, Cochrane, Google Scholar, Clinicaltrials.gov, ITCRP, and EudraCT from database inception to 22 September 2025. The searches were conducted between 19 and 22 September 2025 for controlled trials comparing any ARB to placebo or other preventive migraine drugs in individuals with episodic or chronic migraine. Guidelines, letters, editorials, narrative reviews, case reports, and news were excluded. Summary data were extracted by two reviewers, and random-effects meta-analyses were performed, with heterogeneity assessed using Cochrane I2 statistic. Primary outcomes were monthly headache/migraine days or attacks, and response rates. Adverse event occurrence was also assessed. The risk of bias was assessed using the Cochrane RoB2 tool and the certainty of evidence was assessed using GRADEpro. The study was pre-registered in Prospero (CRD42023405372) and received no funding.ResultsFour trials published between 2003 and 2025 were included in the meta-analysis: three RCTs on candesartan, and one on telmisartan. All four studies reported the outcomes migraine days and responder (≥50% reduction of migraine days) rates, and three reported headache days.…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 659 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.